Diabetes medications

Add-on treatment with subcutaneous semaglutide 2.4 mg produces a marked increase in weight loss for people without diabetes undertaking an intensive lifestyle intervention to combat obesity, report the STEP 3 investigators in JAMA.

The SGLT2 inhibitor canagliflozin reduces blood pressure and the need for additional antihypertensives in people with type 2 diabetes and chronic kidney disease, research suggests.

The latest report from the CORONADO study reveals factors predictive of home discharge within 28 days among people with diabetes hospitalized with COVID-19, as well as those linked to mortality risk.

Empagliflozin treatment significantly reduces pulmonary artery blood pressure in patients with heart failure, show findings from the randomized EMBRACE-HF trial.

Findings from a pilot study suggest that the GLP-1 receptor agonist liraglutide might be beneficial for the management of obesity in people with schizophrenia, schizoaffective disorder, or first-episode psychosis.

Lead author of the STEP 1 trial, John Wilding, discusses the findings and what they may mean for the treatment of people with obesity (5:42)

Read our round-up the STEP phase 3 trials of semaglutide 2.4 mg in people with obesity, plus the SELECT cardiovascular outcomes trial.

Findings of the STEP 1 study show marked weight loss in people with obesity but without type 2 diabetes during over a year of treatment with a high dose of semaglutide.

Among people with type 1 diabetes, adding the SGLT2 inhibitor empagliflozin to an automated insulin delivery system may allow replacement of carbohydrate counting with a simple meal announcement, suggest findings from a pilot randomized trial.

Findings from EMPEROR-Reduced show that people with heart failure benefit from SGLT2 inhibition even if they are already taking a neprilysin inhibitor.

Results from the CORONADO study indicate that use of DPP-4 inhibitors does not affect outcomes for people with type 2 diabetes admitted to hospital with COVID-19.

Researchers find that older adults with diabetes are frequently treated to an intensive glycemic target, putting them at risk for poor outcomes, particularly when high-risk agents are used.

Use of the SGLT2 inhibitor dapagliflozin is associated with a reduced risk for new-onset type 2 diabetes in high-risk individuals with heart failure and reduced ejection fraction, suggests an exploratory analysis of data from the DAPA-HF trial.

A network meta-analysis highlights the impact of individual risk profiles on the absolute benefits offered by GLP-1 receptor agonists and SGLT2 inhibitors for people with type 2 diabetes.